EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Novel Cyclized Hexapeptide‐9 Outperforms Retinol Against Skin Aging: A Randomized, Double‐Blinded, Active‐ and Vehicle‐Controlled Clinical Trial

Huailong Chang, Kan Tao, Yuge Yang, Yanling Wang, Mengru Ge, Xiaoli Wang, Shengnan Tang, Haining Yu

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70290 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Huailong Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Global R&D Center, Shanghai Chicmax Cosmetic Co. Ltd., Shanghai, China. Hauptthemen laut MEDLINE: Oligopeptides, Peptides, Cyclic, Skin Aging, Vitamin A. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The functionality and regenerative capacity of skin progressively deteriorate with aging. Topical use of peptides with a hyper‐safety profile has been implicated in replacing retinol for skin anti‐aging use, but is limited due to low stability and poor skin permeability.

Aims

In this randomized, double‐blinded, active‐ and vehicle‐controlled clinical trial, we aim to evaluate the efficacy of an innovative cyclized hexapeptide‐9 (CHP‐9) with increased stability and skin permeability on skin aging compared to retinol.

Methods

Healthy volunteers with aging skin were randomly assigned to twice‐daily topical use of 0.002% CHP‐9 serum, 0.002% retinol serum, or vehicle serum for 56 days.

Results

CHP‐9 treatment significantly decreased the number, area, and roughness of both crow's feet (−2.20, 95% CI: −4.38, −0.03; −3.95, 95% CI: −5.80, −2.11; −1.95, 95% CI: −3.30, −0.59, respectively) and forehead wrinkles (−2.88, 95% CI: −4.21, −1.56; −4.90, 95% CI: −5.97, −3.82; −3.96, 95% CI: −5.92, −2.01, respectively), while retinol only decreased the area of crow's feet (−2.23, 95% CI: −3.86, −0.60) and the number and area of forehead wrinkles (−1.05, 95% CI:‐1.69, −0.41). Except for the roughness of crow's feet, CHP‐9 demonstrated significantly larger extent of effects than retinol did on all other outcomes. Furthermore, long‐term use of CHP‐9 showed time‐dependent augmentation in its potency to reduce the number of crow's feet, and the number, area, and roughness of forehead wrinkles.

Conclusions

In conclusion, CHP‐9 is more potent than retinol in improving skin aging‐related symptoms, especially for long‐term use. Cyclization of collagen peptides may present a preventive/therapeutic option for skin aging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligopeptidesPeptides, CyclicSkin AgingVitamin AAdultAgedFemaleHumansMaleMiddle AgedAdministration, CutaneousDouble-Blind MethodHealthy VolunteersSkinTreatment Outcome

Stichwörter der Autor:innen

clinical trialcyclized hexapeptide‐9efficacy evaluationretinolskin agingwrinkles

Substanzen

OligopeptidesPeptides, CyclicVitamin A

Autor:innen und Institutionen

  • Global R&D Center, Shanghai Chicmax Cosmetic Co. Ltd., Shanghai, China.
  • Shanghai Kans Biotech Co. Ltd., Shanghai, China.

Zitieren

APA

Chang, H., Tao, K., Yang, Y., Wang, Y., Ge, M., Wang, X., Tang, S., & Yu, H. (2025). Novel Cyclized Hexapeptide‐9 Outperforms Retinol Against Skin Aging: A Randomized, Double‐Blinded, Active‐ and Vehicle‐Controlled Clinical Trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70290

Vancouver

Chang H, Tao K, Yang Y, Wang Y, Ge M, Wang X, et al. Novel Cyclized Hexapeptide‐9 Outperforms Retinol Against Skin Aging: A Randomized, Double‐Blinded, Active‐ and Vehicle‐Controlled Clinical Trial. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70290

BibTeX
@article{Chang2025,
  author = {Chang, Huailong and Tao, Kan and Yang, Yuge and Wang, Yanling and Ge, Mengru and Wang, Xiaoli and Tang, Shengnan and Yu, Haining},
  title = {Novel Cyclized Hexapeptide‐9 Outperforms Retinol Against Skin Aging: A Randomized, Double‐Blinded, Active‐ and Vehicle‐Controlled Clinical Trial},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70290}
}
Kostenlos starten →